Bictegravir

Drug Profile

Bictegravir

Alternative Names: GS 9883

Latest Information Update: 23 Feb 2017

Price : $50

At a glance

  • Originator Gilead Sciences
  • Class Antivirals; Oxazepines; Pyrazines; Pyridones; Small molecules
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued HIV-1 infections

Most Recent Events

  • 13 Feb 2017 Safety, efficacy and immunogenicity data from a phase II trial in HIV infections released by Gilead Sciences
  • 20 Jun 2016 Adverse events data from a phase I trial in HIV-1 infections presented at American Society for Microbiology Conference (ASM-2016)
  • 17 May 2016 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top